PT3079675T - Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal - Google Patents
Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinalInfo
- Publication number
- PT3079675T PT3079675T PT148099088T PT14809908T PT3079675T PT 3079675 T PT3079675 T PT 3079675T PT 148099088 T PT148099088 T PT 148099088T PT 14809908 T PT14809908 T PT 14809908T PT 3079675 T PT3079675 T PT 3079675T
- Authority
- PT
- Portugal
- Prior art keywords
- nicotinamide
- modifying
- pharmaceutical composition
- composition containing
- nicotinic acid
- Prior art date
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 3
- 235000005152 nicotinamide Nutrition 0.000 title 2
- 239000011570 nicotinamide Substances 0.000 title 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 244000005709 gut microbiome Species 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 229960003966 nicotinamide Drugs 0.000 title 1
- 229960003512 nicotinic acid Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197283 | 2013-12-13 | ||
| EP14154543 | 2014-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3079675T true PT3079675T (pt) | 2020-03-05 |
Family
ID=52021224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT148099088T PT3079675T (pt) | 2013-12-13 | 2014-12-12 | Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10888555B2 (https=) |
| EP (1) | EP3079675B1 (https=) |
| JP (2) | JP6895752B2 (https=) |
| DK (1) | DK3079675T3 (https=) |
| ES (1) | ES2788866T3 (https=) |
| HU (1) | HUE048488T2 (https=) |
| PL (1) | PL3079675T3 (https=) |
| PT (1) | PT3079675T (https=) |
| WO (1) | WO2015086843A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015086838A2 (en) | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| BR112018071370A2 (pt) | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de mesalazina |
| TW201739455A (zh) | 2016-04-19 | 2017-11-16 | 菲林公司 | 菸鹼醯胺的口服醫藥組成物 |
| US10815184B2 (en) * | 2016-06-13 | 2020-10-27 | Syneurx International (Taiwan) Corp. | Co-crystals of lithium benzoate and uses thereof |
| US11008277B2 (en) * | 2016-06-13 | 2021-05-18 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
| WO2018198842A1 (ja) * | 2017-04-23 | 2018-11-01 | 国立大学法人九州大学 | 非アルコール性脂肪性肝疾患用治療剤 |
| EP3398600A1 (en) * | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Modified release nicotinamide |
| EP3398601A1 (en) * | 2017-05-02 | 2018-11-07 | Salmon Pharma GmbH | Nicotinamide for treating dyslipidemia |
| CN111295190A (zh) * | 2017-10-30 | 2020-06-16 | 荷兰联合利华有限公司 | 烟酰胺用于微生物组平衡的用途 |
| US20220249535A1 (en) * | 2019-04-05 | 2022-08-11 | Rejuvenation Therapeutics | Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof |
| CN113893262A (zh) * | 2021-09-29 | 2022-01-07 | 武汉英纽林生物科技有限公司 | 一种用于干预糖尿病前期空腹血糖偏高的nad+组合物及其制备方法和使用方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5736532A (en) | 1996-02-14 | 1998-04-07 | Furda; Ivan | Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan |
| GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| US6713057B1 (en) * | 1999-02-24 | 2004-03-30 | The Johns Hopkins University | Compositions and methods for modulating serum cholesterol |
| GB0015242D0 (en) | 2000-06-22 | 2000-08-16 | Nycomed Amersham Plc | Stabiliser for radiopharmaceuticals |
| WO2002011725A1 (en) | 2000-08-08 | 2002-02-14 | Shionogi & Co., Ltd. | Inflammatory cytokine production inhibitors |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| AU2004314731B2 (en) | 2004-01-20 | 2011-07-07 | The Board Of Regents Of The University Of Oklahoma | Compositions and methods of treatment for inflammatory diseases |
| US20060264409A1 (en) | 2004-01-20 | 2006-11-23 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
| US7326809B2 (en) | 2004-05-27 | 2008-02-05 | Antibe Therapeutics Inc. | Salts of 4- or 5-aminosalicylic acid |
| EP1802287A2 (en) | 2004-09-27 | 2007-07-04 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
| JPWO2007004613A1 (ja) | 2005-07-01 | 2009-01-29 | 味の素株式会社 | 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤 |
| ITMI20061932A1 (it) | 2006-10-09 | 2008-04-10 | Carlo Ghisalberti | Complessi a trasferimento di carica per uso medicale |
| WO2009051609A1 (en) | 2007-10-19 | 2009-04-23 | Pardee Joel D | Metabolic enhancement therapy |
| US20110104282A1 (en) | 2008-04-25 | 2011-05-05 | Karolinska Institutet Innovations Ab | New Therapy of Treatment of the Irritable Bowel Syndrome |
| US20110123575A1 (en) * | 2008-06-02 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Modified release niacin formulations |
| JP5740306B2 (ja) | 2008-10-03 | 2015-06-24 | ドクトル ファルク ファルマ ゲーエムベーハー | メサラミン顆粒を用いて腸疾患を治療するための組成物および方法 |
| JP2011121889A (ja) | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| JP2012102054A (ja) | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | 腸内ポリアミン増強剤 |
| WO2012090224A1 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug |
| DK2861229T3 (da) | 2012-06-15 | 2021-01-18 | Conaris Res Institute Ag | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
| US10456389B2 (en) | 2013-06-14 | 2019-10-29 | Conaris Research Institute Ag | Extended release nicotinamide formulation |
| WO2015086838A2 (en) | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| TW201739455A (zh) | 2016-04-19 | 2017-11-16 | 菲林公司 | 菸鹼醯胺的口服醫藥組成物 |
-
2014
- 2014-12-12 HU HUE14809908A patent/HUE048488T2/hu unknown
- 2014-12-12 JP JP2016538751A patent/JP6895752B2/ja active Active
- 2014-12-12 WO PCT/EP2014/077646 patent/WO2015086843A2/en not_active Ceased
- 2014-12-12 US US15/103,410 patent/US10888555B2/en active Active
- 2014-12-12 PL PL14809908T patent/PL3079675T3/pl unknown
- 2014-12-12 PT PT148099088T patent/PT3079675T/pt unknown
- 2014-12-12 ES ES14809908T patent/ES2788866T3/es active Active
- 2014-12-12 EP EP14809908.8A patent/EP3079675B1/en active Active
- 2014-12-12 DK DK14809908.8T patent/DK3079675T3/da active
-
2019
- 2019-06-03 JP JP2019103443A patent/JP7387299B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE048488T2 (hu) | 2020-07-28 |
| DK3079675T3 (da) | 2020-04-20 |
| WO2015086843A3 (en) | 2015-08-06 |
| EP3079675A2 (en) | 2016-10-19 |
| JP7387299B2 (ja) | 2023-11-28 |
| US20170027924A1 (en) | 2017-02-02 |
| PL3079675T3 (pl) | 2020-07-27 |
| ES2788866T3 (es) | 2020-10-23 |
| JP2019189616A (ja) | 2019-10-31 |
| JP2017500311A (ja) | 2017-01-05 |
| WO2015086843A2 (en) | 2015-06-18 |
| EP3079675B1 (en) | 2020-02-12 |
| JP6895752B2 (ja) | 2021-06-30 |
| US10888555B2 (en) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3079675T (pt) | Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal | |
| IL236205A0 (en) | A pharmaceutical composition containing nicotinic acid and/or nicotamide and/or tryptophan to have a positive effect on the intestinal microbiota | |
| ZA201708460B (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| DK2923289T3 (da) | Tidssynkroniseringsforbedringer for samarbejdende medicinske anordninger | |
| IL238060B (en) | 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them | |
| PL2998296T3 (pl) | Pochodna kwasu cykloalkilowego, sposób jej otrzymywania i jej zastosowanie farmaceutyczne | |
| ZA201603629B (en) | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation | |
| EP3020417A4 (en) | Pharmaceutical composition for respiratory administration | |
| IL245415A0 (en) | A process for the preparation of methylphenidate and its pharmaceutical salts | |
| IL237278A0 (en) | Consequences of pyridine and medicine | |
| PL2789607T3 (pl) | Pochodna pirydonu i lek zawierający tę pochodną | |
| PL399613A1 (pl) | Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie | |
| ZA201408723B (en) | Emulsion for pharmaceutical use and method for the production thereof | |
| HUP1300648A2 (hu) | Dabigatran és származékainak komplexei,elõállításuk és gyógyszerészeti kompozícióik | |
| EP3071195A4 (en) | Regimen and method for treatment of type 2 diabetes | |
| TH1401007439A (th) | องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้ | |
| AU2013904467A0 (en) | Regimen and method for treatment of type 2 diabetes | |
| HUP1400084A2 (hu) | Dabigatran és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |